NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
beta Lactamase Inhibitors
Pharmacologic Class:
beta Lactamase Inhibitor
Indications (7)
olderno alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coliKlebsiella pneumoniaeKlebsiella oxytocaEnterobacter cloacae complexCitrobacter freundii complexSerratia marcescens
Clinical Trials (1)
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
Started Apr 2023
48 enrolled
Gram-negative Bacterial Infections
Loss of Exclusivity
LOE Date
Jun 15, 2032
76 months away
Patent Expiry
Jun 15, 2032
Exclusivity Expiry
Feb 7, 2033